Antithrombotic treatment in elderly patients with Atrial fibrillation;Tratamiento antitrombótico en el paciente anciano con fibrilación auricular

Revista Clinica Espanola

Volumn 215, Issue 3, 2015, Pages 171-181

  Suarez Fernandez C ^a   Camafort, M ^b   Cepeda Rodrigo, J M ^c   Diez Manglano J ^d   Formiga, F ^e   Pose Reino, A ^f   Tiberio, G ^g   Mostaza, J M ^h  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL VEGA BAJA   (Spain)

^d HOSPITAL ROYO VILLANOVA   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g Instituto de Investigación Sanitaria de Navarra   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antagonistas de la vitamina K; Apixaban; Dabigatran; Edoxaban; Fibrilaci n auricular no valvular; Gu as; Palabras clave Anciano; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; HUMAN;

EID: 84930479768     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2014.11.024     Document Type: Article

References (54)

1. S.A. Lubitz, K.A. Bauer, E.J. Benjamin, R.W. Besdine, D.E. Forman, and M.E. Gurol Stroke prevention in atrial fibrillation in older adults: Existing knowledge gaps and areas for innovation: A summary of an American Federation for Aging research seminar J Am Geriatr Soc 61 2013 1798 1803
2. A.S. Go, E.M. Hylek, K.A. Phillips, Y. Chang, L.E. Henault, and J.V. Selby Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375
3. J. Heeringa, D.A.M. Van der Kuip, A. Hofman, J.A. Kors, G. Van Herpen, and B. Stricker Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study Eur Heart J 27 2006 949 953
4. V. Barrios, A. Calderón, C. Escobar, and M. De la Figuera Pacientes con fibrilación auricular asistidos en consultas de atención primaria. Estudio Val-FAAP Rev Esp Cardiol 65 2012 47 53
5. J.J. Gómez-Doblas, J. Muñiz, J.J. Martin, G. Rodríguez-Roca, J.M. Lobos, and P. Awamleh Prevalencia de fibrilación auricular en España. Resultados del estudio OFRECE Rev Esp Cardiol 67 2014 259 269
6. J.M. Baena-Díez, M. Grau, R. Forés, D. Fernández-Bergés, R. Elosua, M. Sorribes en representación del estudio DARIOS Prevalencia de fibrilación auricular y factores asociados en España, análisis de seis estudios de base poblacional. Estudio DARIOS Rev Clin Esp 214 2014 505 512
7. A. López Soto, F. Formiga, X. Bosch, J. García Alegría en representación de los investigadores del estudio ESFINGE Prevalencia de la fibrilación auricular y factores relacionados en pacientes ancianos hospitalizados: estudio ESFINGE Med Clin (Barc) 138 2012 231 237
8. M. Rodríguez-Mañero, V. Bertomeu-González, A. Cordero, J. Moreno-Arribas, P. Mazón, and L. Fácila Trends in clinical profile and medical treatments of atrial fibrillation patients over the last 10 years Rev Port Cardiol 32 2013 103 109
9. V. Barrios, C. Escobar, and R. Echarri Atrial fibrillation and coronary heart disease: Fatal attraction J Atr Fibrillation 1 2009 262 269
10. J.E. Freedman, and B.J. Gersh Atrial fibrillation and stroke prevention in aging patients: What's good can be even better Circulation 130 2014 129 131
11. L. Mérida-Rodrigo, F. Poveda-Gómez, M. Camafort-Babkowski, F. Rivas-Ruiz, M.D. Martín-Escalante, and R. Quirós-López Supervivencia a largo plazo del ictus isquémico Rev Clin Esp 212 2012 223 228
12. O. Hanon, P. Assayag, J. Belmin, J.P. Collet, J.P. Emeriau, and L. Fauchier French society of geriatrics and gerontology and the French society of cardiology. Expert consensus of the French society of geriatrics and gerontology and the French society of cardiology on the management of atrial fibrillation in elderly people Geriatr Psychol Neuropsychiatr Vieil 11 2013 117 143
13. S. Naderi, Y. Wang, A.L. Miller, F. Rodriguez, M.K. Chung, and M.J. Radford The impact of age on the epidemiology of atrial fibrillation hospitalizations Am J Med 127 2014 e1 e7
14. J. Montes-Santiago, V. Rodil, F. Formiga, J.M. Cepeda, and A. Urrutia Características y costes de los pacientes ingresados por arritmias cardiacas en España Rev Clin Esp 213 2013 235 239
15. C.S. Kwok, Y.K. Loke, R. Hale, J.F. Potter, and P.K. Myint Atrial fibrillation and incidence of dementia: A systematic review and meta-analysis Neurology 76 2011 914 922
16. O.M. Rønning, and K. Stavem Predictors of mortality following acute stroke: A cohort study with 12 years of follow-up J Stroke Cerebrovasc Dis 21 2012 369 372
17. A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, and S. Ernst Guidelines for the management of atrial fibrillation: The Task Force for the Management of atrial fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
18. A.J. Camm, G.Y. Lip, R. de Caterina, I. Savelieva, D. Atar, and S.H. Hohnloser 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
19. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey Chest 138 2010 1093 1100
20. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation Chest 137 2010 263 272
21. T. Nantsupawat, K. Nugent, and A. Phrommintikul Atrial fibrillation in the elderly Drugs Aging 30 2013 593 601
22. N. Mavaddat, A. Roalfe, K. Fletcher, G.Y. Lip, F.D. Hobbs, and D. Fitzmaurice Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: Randomized controlled trial (Birmingham atrial fibrillation treatment of the aged study) Stroke 45 2014 1381 1386
23. M.S. Sibai, F. Bellarbre, N. Ghazali, M.L. Bureau, M. Priner, and P. Ingrand Decisional algorithm to prescribe vitamin K antagonist in geriatric patients with atrial fibrillation Geriatr Psychol Neuropsychiatr Vieil 12 2014 20 24
24. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
25. M.I. Aguilar, R. Hart, and L.A. Pearce Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks Cochrane Database Syst Rev 3 2007 CD006186
26. J. Mant, F.D. Hobbs, K. Fletcher, A. Roalfe, D. Fitzmaurice, G.Y. Lip BAFTA investigators; Midland Research Practices Network (MidReC) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial Lancet 370 2007 493 503
27. G.Y. Lip, and D.A. Lane Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation - focus on the elderly Circ J 77 2013 1380 1388
28. C.W. Siu, and H.F. Tse Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation Circ Arrhythm Electrophysiol 7 2014 300 306
29. D.E. Singer, Y. Chang, M.C. Fang, L.H. Borowsky, N.K. Pomernacki, and N. Udaltsova Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation: The ATRIA study Circ Cardiovasc Qual Outcomes 2 2009 297 304
30. F. Formiga, A. Ferrer, E. Henríquez, and R. Pujol Bajo porcentaje de anticoagulación oral en nonagenarios con fibrilación auricular Rev Clin Esp 206 2006 410 411
31. B.F. Gage, M. Boechler, A.L. Doggette, G. Fortune, G.C. Flaker, and M.W. Rich Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation Stroke 31 2000 822 827
32. W.Q. Gao, Y.T. Guo, J.L. Ma, P. Zhu, and Y.T. Wang Analysis of antithrombotic therapy in elderly patients with atrial fibrillation Genet Mol Res 13 2014 736 743
33. S.W. Darnell, S.C. Davis, J.J. Whitcomb, J.A. Manfredi, and B.T. McLaurin Bleeding risk factors affecting warfarin therapy in the elderly with atrial fibrillation Dimens Crit Care Nurs 33 2014 57 63
34. C. Fuenzalida, B. Coll-Vinent, M. Navarro, A. Cervera, M. Camafort, L. Mont en nombre de la Unidad de Fibrilación Auricular del Hospital Clínic de Barcelona (UFA) Evolución temporal del tratamiento de los pacientes con fibrilación auricular en un área sanitaria urbana Med Clin (Barc) 2014 pii: S0025-7753(14)00191-2
35. T.S. Inui, R. Parina, D.C. Chang, T.S. Inui, and R. Coimbra Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter: A long-term analysis of risk versus benefit J Trauma Acute Care Surg 76 2014 642 649
36. C. Cameron, D. Coyle, T. Richter, S. Kelly, K. Gauthier, and S. Steiner Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation BMJ Open 4 2014 e004301
37. J.W. Eikelboom, L. Wallentin, S.J. Connolly, M. Ezekowitz, J.S. Healey, and J. Oldgren Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation 123 2011 2363 2372
38. E. Berthelot, C. Lavenu-Bombled, L. Orostegui-Giron, C. Desconclois, and P. Assayag Impaired renal function and bleeding in elderly treated with dabigatran Blood Coagul Fibrinolysis 25 2014 618 620
39. J.L. Halperin, G.J. Hankey, D.M. Wojdyla, J.P. Piccini, Y. Lokhnygina, M.R. Patel on behalf of the ROCKET AF Steering Committee and Investigators Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET AF trial Circulation 130 2014 138 146
40. S. Halvorsen, D. Atar, H. Yang, R. de Caterina, C. Erol, and D. Garcia Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial Eur Heart J 35 2014 1864 1872
41. P. Sardar, S. Chatterjee, S. Chaudhari, and G.Y. Lip New oral anticoagulants in elderly adults: Evidence from a meta-analysis of randomized trials J Am Geriatr Soc 62 2014 857 864
42. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
43. ®. Resumen de las características del producto [actualizado 24 Oct 2014]. Disponible en: http://www.ema.europa.eu/docs/es-ES/document-library/EPAR-Product-Information/human/000829/WC500041059.pdf
44. ®. Resumen de las características del producto [actualizado 8 Oct2014]. Disponible en: http://www.ema.europa.eu/docs/es-ES/document-library/EPAR-Product-Information/human/000944/WC500057108.pdf.
45. ®. Resumen de las características del producto [actualizado 29 Sep 2014]. Disponible en: http://www.ema.europa.eu/docs/es-ES/document-library/EPAR-Product-Information/human/002148/WC500107728.pdf
46. L.B. Goldstein, C.D. Bushnell, R.J. Adams, L.J. Appel, L.T. Braun, and S. Chaturvedi Guidelines for the primary prevention of stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 42 2011 517 584
47. A.C. Skanes, J.S. Healey, J.A. Cairns, P. Dorian, A.M. Gillis, and M.S. McMurtry Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: Recommendations for stroke prevention and rate/rhythm control Can J Cardiol 28 2012 125 136
48. J.J. You, D.E. Singer, P.A. Howard, D.A. Lane, M.H. Eckman, and M.C. Fang Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl 2012 e531S-75S
49. H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, and J. Oldgren European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
50. B. Fuentes, J. Gállego, A. Gil-Nuñez, A. Morales, F. Purroy, and J. Roquer Guía para el tratamiento preventivo del ictus isquémico y AIT (II). Recomendaciones según subtipo etiológico Neurologia 29 2014 168 183
51. C.T. January, L.S. Wann, J.S. Alpert, H. Calkins, J.C. Cleveland Jr., and J.E. Cigarroa 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society Circulation 130 2014 2071 2104
52. A. Culebras, S.R. Messé, S. Chaturvedi, C.S. Kase, and G. Gronseth Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology Neurology 82 2014 716 724
53. National Institute for Health and Clinical Excellence (NICE). Atrial fibrillation: The management of atrial fibrillation. June 2014 [actualizado Ago 2014]. Disponible en: www.nice.org.uk/guidance/CG180
54. De Andrés-Nogales F, Oyagüez I, Betegón-Nicolás L, Canal-Fontcuberta C, Soto-Álvarez J. Situación del tratamiento anticoagulante oral en pacientes con fibrilación auricular no valvular en España. Estudio REACT-AF. Rev Clin Esp. 2014 en prensa.